Literature DB >> 14635824

Pain clinicians' rankings of aberrant drug-taking behaviors.

Steven D Passik1, Kenneth L Kirsh, Laurie Whitcomb, Pamela K Dickerson, Dale E Theobald.   

Abstract

A pilot study was conducted to examine experienced pain physicians' perceptions of aberrant drug taking behaviors. One hundred pain physicians attending a meeting on pain management were asked to rank order (from most aberrant = 1 to least aberrant = 13) a list of aberrant drug-taking behaviors. The sample was comprised mainly of anesthesiologists (50%) and half of the group had 10 or more years of pain management experience. The group prescribed an average of 19-96 opioid medications per week. Practice variables were not related to the rank ordering of the behaviors. All of the various behaviors appeared in all 13 of the rank ordering slots, suggesting a great deal of individual difference in the perception of these behaviors. By examining the average ranking of the behaviors, we noted that physicians' focus on illegal behaviors as the most aberrant followed by the alteration of route of delivery and self-escalation of dose. This survey suggests that an experienced group of pain clinicians does not view aberrant drug related behaviors uniformly. Average rankings suggest clinicians seem to view illegal behavior as the most worrisome. These results must be interpreted with caution due to the small convenience sample, the lack of data on the level of addiction medicine training of the respondents and the lack of data on those physicians who chose not to respond. Further inquiry could be used to guide clinicians' responses to aberrant behaviors when encountered in patients on controlled substances for pain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14635824     DOI: 10.1080/j354v16n04_04

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  9 in total

Review 1.  Misuse of and dependence on opioids: study of chronic pain patients.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Douglas Gourlay; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

2.  Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.

Authors:  Jessica J Wyse; Benjamin J Morasco; Steven K Dobscha; Michael I Demidenko; Thomas H A Meath; Travis I Lovejoy
Journal:  J Opioid Manag       Date:  2018 Jul/Aug

Review 3.  "Safe and effective when used as directed": the case of chronic use of opioid analgesics.

Authors:  Jane C Ballantyne
Journal:  J Med Toxicol       Date:  2012-12

Review 4.  Adherence monitoring with chronic opioid therapy for persistent pain: a biopsychosocial-spiritual approach to mitigate risk.

Authors:  Deborah Matteliano; Barbara J St Marie; June Oliver; Candace Coggins
Journal:  Pain Manag Nurs       Date:  2012-10-23       Impact factor: 1.929

5.  Addiction Severity Index in a chronic pain sample receiving opioid therapy.

Authors:  Kenneth Saffier; Cynthia Colombo; David Brown; Marlon P Mundt; Michael F Fleming
Journal:  J Subst Abuse Treat       Date:  2007-03-21

6.  Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals.

Authors:  Luke Hansen; Joanne Penko; David Guzman; David R Bangsberg; Christine Miaskowski; Margot B Kushel
Journal:  J Pain Symptom Manage       Date:  2011-07-30       Impact factor: 3.612

7.  Providers' experiences treating chronic pain among opioid-dependent drug users.

Authors:  Karina M Berg; Julia H Arnsten; Galit Sacajiu; Alison Karasz
Journal:  J Gen Intern Med       Date:  2009-02-03       Impact factor: 5.128

Review 8.  Assessing aberrant drug-taking behaviors in the patient with chronic pain.

Authors:  Steven D Passik; Kenneth L Kirsh
Journal:  Curr Pain Headache Rep       Date:  2004-08

9.  Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients.

Authors:  Michael F Fleming; James Davis; Steven D Passik
Journal:  Pain Med       Date:  2008-08-18       Impact factor: 3.750

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.